#TVTX
LightNews LightNews
orrery.bsky.social
[CHUU-ing] CHUU's Recommendation for Workers💗 | KWCWS Workers' Insurance Shoot Behind-the-Scenes
m.youtube.com/watch?v=tvTX...
[CHUU-ing] 일하는 사람들을 위한 츄의 츄천💗 | 근로복지공단 고용 산재 보험 촬영 비하인드
YouTube video by CHUU Official
m.youtube.com
February 18, 2025 at 9:03 AM
marketwirenews.com
Breaking News: ( NASDAQ: #TVTX ) Buy Recommendation Issued On TVTX By Citigroup

#StockMarket #News
September 6, 2024 at 3:25 PM
marketwirenews.com
Breaking News: ( NASDAQ: #TVTX ) (TVTX) Technical Pivots with Risk Controls

#StockMarket #News
October 14, 2024 at 6:45 PM
biotechhangout.bsky.social
#BiotechHangout Chris Garabedian, Tess Cameron, Eric Schmidt, Sam Fazeli, Brad Loncar on $LBRX IPO, $TRML, policy: China, DTC attack, $RNA data/offering, #WCLC: $SMMT, $TIL, $RVMD, $DNTH, regulatory: $ICPT, Capsida, $SLNO, $FGEN, $CAPR, $TVTX, Arena Bioworks CEO, $NVO layoffs bit.ly/46xsgm1
September 12, 2025 at 1:01 PM
marketwirenews.com
JUST IN: ( NASDAQ: #TVTX ) TVTX Price Target Alert: $20.00. Issued by Bank of America Securities

#StockMarket #News
October 9, 2024 at 4:40 PM
rheaultm.bsky.social
The US sparsentan REMS requirements have been updated and now require Q3 month liver labs instead of monthly. ir.travere.com/press-releas...
Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy
FDA simplifies liver monitoring schedule from monthly to every three months for the duration of treatment and removes embryo-fetal toxicity REMS monitoring Travere Therapeutics, Inc., (Nasdaq: TVTX) t...
ir.travere.com
August 28, 2025 at 10:50 PM
marketwirenews.com
Just In: ( NASDAQ: #TVTX ) Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

#StockMarket #News
October 9, 2024 at 4:45 PM
kidneystories.bsky.social
A Look At Travere Therapeutics (TVTX) Valuation After FDA Expands FILSPARI Approval For FSGS - goo.gl/alerts/5K1mJ2 #GoogleAlerts
A Look At Travere Therapeutics (TVTX) Valuation After FDA Expands FILSPARI Approval For FSGS - Simply Wall St News
Travere Therapeutics (TVTX) is in focus after the FDA granted full approval to FILSPARI to reduce proteinuria in adults and children with focal segmental glomerulosclerosis without nephrotic syndrome,...
goo.gl
April 19, 2026 at 12:18 PM
theoptionsbully2.bsky.social
$SNAP $SYM $TE $WDC $ZETA $LUMN $NOK $PACB $WING $WVE $AMC $CRML $LMND $METC $QUBT $TSSI $FCEL $TVTX $ALT $BHVN $FUBO $REPL $WRD $ATEC $IM $IRBT $NAKA $PENG $WTRG $MNOV

www.patreon.com/posts/142696...
💎 10/31/25-Part 2
💎IV Change Details For 100+ Stocks (Secondary Unusual Options Alert)
November 3, 2025 at 3:06 AM
stocktitan.net
#TVTX Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

https://www.stocktitan.net/news/TVTX/travere-therapeutics-presents-long-term-open-label-extension-data-sv9j013avzrw.html
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
Travere Therapeutics (Nasdaq: TVTX) presented long-term open-label extension data from the Phase 3 DUPLEX study of FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS) at the 63rd ERA 2026 Congress.Patients maintained durable, clinically meaningful proteinuria reductions for up to approximately five years with a safety profile generally consistent with prior findings.
www.stocktitan.net
June 4, 2026 at 2:09 PM
stocktitan.net
#TVTX Travere Therapeutics Announces Planned Chief Executive Officer Transition

https://www.stocktitan.net/news/TVTX/travere-therapeutics-announces-planned-chief-executive-officer-cdyr4263ldyl.html?utm_source=stocktitan-bluesky&utm_medium=social
Travere Therapeutics Announces Planned Chief Executive Officer Transition
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
September 21, 2026 at 8:05 PM
quant-hub.bsky.social
🚨 $TVTX
(b)(c)(d) On September 21, 2026, Travere Therapeutics, Inc. and Eric Dube, Ph.D., mutually agreed to the timeline and terms surrounding the planned transition of Dr. Dube, who will step down from his position as the Company’s President and Chief Executive Officer and as a member of the Bo...
SEC Filing: TVTX
Click to view the official SEC document.
www.sec.gov
September 21, 2026 at 8:11 PM
notreload.bsky.social
#$TVTX shares surged 12% after Q2 results showed FILSPARI sales nearly doubled to $141M, fueled by strong FSGS launch and IgAN growth. notreload.xyz/xy/travere-s...
Travere Stock Jumps on FILSPARI Sales Surge
Travere stock jumps as FILSPARI sales surge, beating forecasts and showing strong patient demand and future growth potential.
notreload.xyz
August 5, 2026 at 8:28 AM
nathandavidowicz.bsky.social
Eglinton LRT on its last day of testing, Ontario extends one fare program
www.youtube.com/watch?v=tvTx... 3.1 mins By CityNews
No Fare Increase in Toronto Area for 2026 & 2027
Eglinton LRT on its last day of testing, Ontario extends one fare program
YouTube video by CityNews
www.youtube.com
December 1, 2025 at 9:43 PM
insiderfinance.com
🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #NVTS 49% OTM
2. #TVTX 30% OTM
3. #U 20% OTM
4. #SNOW 19% OTM
5. #AXTI 18% OTM

#OptionFlow #OptionsTrading #Trading
🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual
January 14, 2026 at 2:20 AM
jonathanpollack.bsky.social
ICYMI: FILSPARI passes a hurdle on the way to FDA approval for FSGS.

#FSGS #NephSky #IgAN #nephrology #kidneydisease
Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that following further review of the supplemental New Drug Applicat...
ir.travere.com
September 11, 2025 at 2:02 AM
merlintrader.bsky.social
Travere Therapeutics (#$TVTX) Stock Hub

Free Biotech Catalyst Calendar on Merlintrader.

www.merlintrader.com/travere-ther...
September 19, 2026 at 7:14 PM
$CCJ-1 $WDC-1 $BPOP-1 $GBTC-1 $AMZU-1 $PRCH-1 $CRCL-1 $XLY-1 $VIXY-1 $SPYM-1 $UL-1 $KBWB-1 $DKNG-1 $PCT-1 $IYW-1 $FLYW-1 $LOPE-1 $FLO-1 $CLM-1 $BATL-1 $CBRL-1 $RGTI-1 $ACAD-1 $IFF-1 $FSLR-1 $KDP-1 $REAL-1 $TVTX-1 $USO-1 $NBIS-1 $UBER-1 $IREN-1 $GRWG-1 $BKR-1
June 10, 2026 at 8:15 PM
merlintrader.bsky.social
Travere Therapeutics ($TVTX) Stock Hub: Operating Income Turns Positive as FILSPARI Sales Climb 96%

https://merlintrader.com/travere-therapeutics-stock-hub/
$TVTX Stock Hub: Operating Income Positive, FILSPARI +96%
Travere posted $3.95M of operating income in Q2 2026 as FILSPARI sales climbed 96% to $141.1M; the wider net loss comes from a $40.0M convertible charge.
merlintrader.com
September 18, 2026 at 10:32 AM
$YOU-1 $HWM-1 $ZTS-1 $AMZN-1 $NKE-1 $SMH-1 $META-1 $VRSK-1 $BDC-1 $KLAR-1 $HGV-1 #$BF.B-1 $FIS-1 $UBER-1 $TSLQ-1 $RBLX-1 $AIQ-1 $ZSL-1 $BKR-1 $VALE-1 $MUB-1 $EXE-1 $BBWI-1 $TVTX-1 $MU-1 $ARKK-1 $DASH-1 $SPCU-1 $GLW-1 $RLAY-1 $AMJB-1 $AESI-1 $GSM-1 $PTIR-1 $SHOP-1
September 10, 2026 at 8:07 PM
merlintrader.bsky.social
Travere Therapeutics ($TVTX) Stock Hub: Operating Income Turns Positive as FILSPARI Sales Climb 96%

https://www.merlintrader.com/travere-therapeutics-stock-hub/
Travere (TVTX): FILSPARI, FSGS Approval & Civorebrutinib
Travere Therapeutics (TVTX): FILSPARI, the FSGS approval, civorebrutinib and the rare kidney disease execution test. Catalysts and risks.
www.merlintrader.com
September 2, 2026 at 7:18 PM
quant-hub.bsky.social
🚨 $TVTX
LYONS GARY A () sold 10,000 shares at an average price of $63.2846 per common share. (Date: 2026-08-18)
SEC Filing: TVTX
Click to view the official SEC document.
www.sec.gov
August 19, 2026 at 8:09 PM
quant-hub.bsky.social
🚨 $TVTX
GARY LYONS, a Director, filed a notice of intent to sell 5,000 shares of common stock, valued at approximately $317,650.00, on 08/18/2026.
SEC Filing: TVTX
Click to view the official SEC document.
www.sec.gov
August 18, 2026 at 9:05 PM
quant-hub.bsky.social
🚨 $TVTX
GARY A LYONS, a Director, filed a notice of intent to sell 5,000 shares of common stock, valued at approximately $310,700.00, on 08/17/2026.
SEC Filing: TVTX
Click to view the official SEC document.
www.sec.gov
August 17, 2026 at 8:57 PM
newsarea.bsky.social
S&CO Inc. Makes New Investment in Travere Therapeutics, Inc. $TVTX

S&CO Inc. acquired a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 56,000 shares of the company’s stock,…
S&CO Inc. Makes New Investment in Travere Therapeutics, Inc. $TVTX
S&CO Inc. acquired a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 56,000 shares of the company’s stock, valued at approximately $3,181,000. S&CO Inc. owned 0.06% of Travere Therapeutics at the end of the most [...]
news-area.com
August 16, 2026 at 10:57 PM